Journal
BONE MARROW TRANSPLANTATION
Volume 56, Issue 8, Pages 1998-2004Publisher
SPRINGERNATURE
DOI: 10.1038/s41409-021-01279-w
Keywords
-
Categories
Funding
- Macrogenics
- Abbvie
- Glycomimetics
- Seattle Genetics
- Immunogen
- Amgen
- Pfizer
- Honoraria/Advisory boards: Kite
- Glycomimetcs
Ask authors/readers for more resources
The safety and efficacy of alloHCT consolidation after blinatumomab for relapsed refractory acute lymphocytic leukemia remains uncertain. Our study of 106 patients who received alloHCT post blinatumomab showed a 2-year progression free survival of 48% and overall survival of 58%. Acute and chronic graft-versus-host disease incidences were 9.9% and 34.4% respectively. Overall survival did not significantly differ between patients who achieved complete remission with MRD negative or positive before alloHCT.
Safety and efficacy of allogeneic hematopoietic stem cell transplantation (alloHCT) consolidation after blinatumomab is largely undetermined. To address this issue, we assembled multi-center data of relapsed refractory (RR) acute lymphocytic leukemia (ALL) patients who received alloHCT after blinatumomab. From December 2014 to May 2019, 223 patients who received blinatumomab for RR ALL outside clinical trials were identified. Among them, 106 (47%) patients transplanted post blinatumomab were evaluated for response and toxicity. Ninety-two (87%) patients received alloHCT after achieving CR, while remaining received subsequent salvage prior to undergoing alloHCT. Progression free survival (PFS) and overall survival (OS) at 2 years post alloHCT was 48% (95% CI: 36-59%) and 58% (95% CI: 45-69%), respectively. The cumulative incidence of GIII-IV aGVHD at 3 months was 9.9% (95% CI: 5.0-16.6%). Similarly, cumulative incidence of moderate to severe cGVHD at 2 years was 34.4% (95% CI: 23.7-45.3%). The overall survival at 2 years was not significantly different in patient who achieved CR with MRD negative (68.4% [95% CI: 28.5-89.1%]) compared to CR with MRD positive (63.4% [95% CI: 47.8-75.4%]) prior to alloHCT (p = 0.8). Our real-world analysis suggests that alloHCT is feasible and effective post blinatumomab in patients with RR ALL.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available